Status:
COMPLETED
Pharmacotherapy Prescribing Pattern and the Adherence Level to Iron Chelation Therapy in Thalassemia
Lead Sponsor:
Reem Ali Shaker
Conditions:
Thalassemia
Eligibility:
All Genders
3-55 years
Brief Summary
Thalassemias are a heterogeneous grouping of genetic disorders that result in dysfunctional Hb, reduced RBC life span leading to chronic anemia . Thalassemia is endemic in the Middle East. Iron chelat...
Detailed Description
Thalassemias are a heterogeneous grouping of genetic disorders that result from a decreased synthesis of alpha or beta chains of hemoglobin resulting in dysfunctional Hb, reduced RBC life span and hem...
Eligibility Criteria
Inclusion
- male and female patients with age above 3 years old diagnosed with thalassemia,
- having iron overload
- taken Iron chelation therapy
- having the acceptance to participate in the study.
Exclusion
- renal and hepatic impairment,
- Allergic to any drug of the study
- history of viral hepatitis or HIV
- Gastrointestinal disorder affecting drug absorption.
- psychiatric disorder affecting consent agreement and unable to comply with study.
Key Trial Info
Start Date :
March 28 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 28 2024
Estimated Enrollment :
199 Patients enrolled
Trial Details
Trial ID
NCT06210139
Start Date
March 28 2023
End Date
February 28 2024
Last Update
July 23 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
AL Zahar teaching Hospital
Najaf, Iraq, 54001